MNTA  Momenta Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

582.5M

Vuru Grade

31.00/100

Current Price

$11.29
+0.14 (+1.26%)

Stability Price

$0.30
Overvalued by 97.31%

Company Metrics

  • 13.83 P/E
  • 13.13 P/S
  • 2.87 P/B
  • -2.193 EPS
  • -146.29% Cash ROIC
  • 11.20 Cash Ratio
  • 0 / 0% Dividend
  • 450,106.00 Avg. Vol.
  • 51.59M Shares
  • 582.5M Market Cap.

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Momenta Pharmaceuticals, Inc. Pushes Forward
Motley Fool - Nov 5, 2014
At this point, earnings calls for Momenta Pharmaceuticals (NASDAQ: MNTA ) are more an opportunity to update investors than to report revenue and earnings.
Momenta Pharmaceuticals Reports Third Quarter 2014 Financial Results - MarketWatch
Momenta Pharmaceuticals Inc.: Momenta Pharmaceuticals Reports Third ... - The Wall Street Transcript
Momenta Pharmaceuticals to Webcast Presentation at Three Upcoming Investor ...
MarketWatch - Nov 6, 2014
About Momenta Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA.
Momenta Pharmaceuticals (MNTA) Posts Quarterly Earnings Results, Misses ... - WKRB News
Momenta Pharmaceuticals Announces Date of Third Quarter 2014 Financial ...
MarketWatch - Oct 22, 2014
Momenta Pharmaceuticals, Inc. MNTA, -1.92% a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the third quarter ended September 30, 2014 before the U.S.
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA ...
PR Newswire (press release) - Oct 17, 2014
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and ...
Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 ...
PipelineReview.com (press release) - Oct 9, 2014
CAMBRIDGE, MA, USA I October 9, 2014 I Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced top-line results from the dose-escalation component (Part A) of ...
Stocks to Track: Momenta Pharmaceuticals, Inc. (MNTA), Fifth Street Finance ...
Techsonian (press release) - Nov 11, 2014
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) declared that it will webcast its presentation at three upcoming investor conferences, 2014 Credit Suisse Healthcare Conference On Wednesday, November 12 at 1:30 p.m.
Hot Stocks: Covisint Corp , Momenta Pharma , Rovi Corp , LivePerson ...
Fico News Media - Nov 10, 2014
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) announces Top-Line Part A results from Phase 1/2 Trial of Necuparanib in patients with pancreatic cancer.
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler Presents at Credit ...
Seeking Alpha (registration) - Nov 13, 2014
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler Presents at Credit Suisse 2014 Healthcare Conference (Transcript). Nov. 12, 2014 7:39 PM ET | About: Momenta Pharmaceuticals, Inc. (MNTA) by: SA Transcripts. Momenta Pharmaceuticals, Inc.
Trending Stocks: BlackBerry Ltd (NASDAQ:BBRY), ACADIA Pharmaceuticals Inc ...
Property Mentor - Nov 14, 2014
On 5 November Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) reported its financial results for the third quarter ended September 30, 2014.
Stock Runners: Microsoft Corporation (NASDAQ:MSFT), Advanced Micro ...
WallStreet Scope - Oct 31, 2014
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the third quarter ended September 30, 2014 before the U.S.